Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses and drug–drug interactions

Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells

(2015) C Arimany-Nardi et al.   PHARMACOGENOMICS JOURNAL

The Poorly Membrane Permeable Antipsychotic Drugs Amisulpride and Sulpiride Are Substrates of the Organic Cation Transporters from the SLC22 Family

(2014) Joao N. Dos Santos Pereira et al.   AAPS Journal

Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors

(2014) C Arimany-Nardi et al.   BRITISH JOURNAL OF PHARMACOLOGY

Genetic Variants in Transcription Factors Are Associated With the Pharmacokinetics and Pharmacodynamics of Metformin

(2014) S Goswami et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genetic polymorphisms and haplotypes of the organic cation transporter 1 gene (SLC22A1) in the Xhosa population of South Africa

(2014) Clifford Jacobs et al.   GENETICS AND MOLECULAR BIOLOGY

Genetic polymorphisms of the organic cation transporter 1 gene (SLC22A1) within the Cape Admixed population of South Africa

(2014) Morne Du Plessis et al.   MOLECULAR BIOLOGY REPORTS

Expression of Drug Transporters and Drug Metabolizing Enzymes in the Bladder Urothelium in Man and Affinity of the Bladder Spasmolytic Trospium Chloride to Transporters Likely Involved in Its Pharmacokinetics

(2014) Maria Bexten et al.   MOLECULAR PHARMACEUTICS

The Cell Line NCl-H441 Is a Useful in Vitro Model for Transport Studies of Human Distal Lung Epithelial Barrier

(2014) Johanna J. Salomon et al.   MOLECULAR PHARMACEUTICS

The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia

(2014) A Di Paolo et al.   PHARMACOGENOMICS JOURNAL

Glucocorticoid receptor regulates organic cation transporter 1 (OCT1, SLC22A1) expression via HNF4α upregulation in primary human hepatocytes

(2014) Alice Rulcova et al.   Pharmacological Reports

OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin

(2014) Ligong Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Influences of Organic Cation Transporter Polymorphisms on the Population Pharmacokinetics of Metformin in Healthy Subjects

(2013) Hwa Yoon et al.   AAPS Journal

Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration

(2013) Mladen V. Tzvetkov et al.   BIOCHEMICAL PHARMACOLOGY

A common novel splice variant ofSLC22A1(OCT1)is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia

(2013) Jacob Grinfeld et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1)

(2013) A. T. Nies et al.   CLINICAL CANCER RESEARCH

Expression ofSLC22A1variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib

(2013) Elisa Herraez et al.   HEPATOLOGY

Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients

(2013) Yuki Ohishi et al.   JOURNAL OF GASTROENTEROLOGY

The SLC22 family with transporters of organic cations, anions and zwitterions

(2013) Hermann Koepsell   MOLECULAR ASPECTS OF MEDICINE

A gene–gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin

(2013) Mette M.H. Christensen et al.   Pharmacogenetics and Genomics

OCT1 genetic variants influence the pharmacokinetics of morphine in children

(2013) Tsuyoshi Fukuda et al.   PHARMACOGENOMICS

Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients

(2012) S. J. Seong et al.   ANNALS OF ONCOLOGY

The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1

(2012) Ali R. Saadatmand et al.   BIOCHEMICAL PHARMACOLOGY

Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake

(2012) Min-Koo Choi et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia

(2012) A. Giannoudis et al.   BLOOD

Pharmacogenomic association between a variant inSLC47A1gene and therapeutic response to metformin in type 2 diabetes

(2012) I. Tkáč et al.   DIABETES OBESITY & METABOLISM

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

(2012) S. Angelini et al.   HAEMATOLOGICA

Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients

(2012) N. Jung et al.   INFECTION

No Correlation between the Expression of FXR and Genes Involved in Multidrug Resistance Phenotype of Primary Liver Tumors

(2012) P. Martinez-Becerra et al.   MOLECULAR PHARMACEUTICS

Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients

(2012) Linda Tarasova et al.   Pharmacogenetics and Genomics

SLC22A1-ABCB1 Haplotype Profiles Predict Imatinib Pharmacokinetics in Asian Patients with Chronic Myeloid Leukemia

(2012) Onkar Singh et al.   PLoS One

Selective Regulation of Cardiac Organic Cation Transporter Novel Type 2 (OCTN2) in Dilated Cardiomyopathy

(2011) Markus Grube et al.   AMERICAN JOURNAL OF PATHOLOGY

Lamotrigine is a substrate for OCT1 in brain endothelial cells

(2011) David Dickens et al.   BIOCHEMICAL PHARMACOLOGY

Association of SLCO1B3 Polymorphism with Intracellular Accumulation of Imatinib in Leukocytes in Patients with Chronic Myeloid Leukemia

(2011) Takeru Nambu et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Genetically Polymorphic OCT1: Another Piece in the Puzzle of the Variable Pharmacokinetics and Pharmacodynamics of the Opioidergic Drug Tramadol

(2011) M V Tzvetkov et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Common 5′-UTR Variant in MATE2-K Is Associated With Poor Response to Metformin

(2011) J H Choi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins

(2011) T. Minematsu et al.   MOLECULAR CANCER THERAPEUTICS

The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c

(2011) Mette M.H. Christensen et al.   Pharmacogenetics and Genomics

DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma

(2011) Elke Schaeffeler et al.   Genome Medicine

OCT1 Expression in Adipocytes Could Contribute to Increased Metformin Action in Obese Subjects

(2010) J. M. Moreno-Navarrete et al.   DIABETES

Common Variants in 40 Genes Assessed for Diabetes Incidence and Response to Metformin and Lifestyle Intervention in the Diabetes Prevention Program

(2010) K. A. Jablonski et al.   DIABETES

Organic Cation Transporter 1 Polymorphisms Predict the Metabolic Response to Metformin in Women with the Polycystic Ovary Syndrome

(2010) Alessandra Gambineri et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

(2010) Naoto Takahashi et al.   JOURNAL OF HUMAN GENETICS

Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents

(2010) Chun-Jung Lin et al.   JOURNAL OF NEUROCHEMISTRY

Genetic Polymorphisms in Organic Cation Transporter 1 (OCT1) in Chinese and Japanese Populations Exhibit Altered Function

(2010) L. Chen et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1

(2010) D L White et al.   LEUKEMIA

hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia

(2010) A Bazeos et al.   LEUKEMIA

Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia

(2010) Margherita Maffioli et al.   LEUKEMIA RESEARCH

Organic Cation Transporters Modulate the Uptake and Cytotoxicity of Picoplatin, a Third-Generation Platinum Analogue

(2010) Swati S. More et al.   MOLECULAR CANCER THERAPEUTICS

OCT2 and MATE1 Provide Bidirectional Agmatine Transport

(2010) Tate N. Winter et al.   MOLECULAR PHARMACEUTICS

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users

(2010) Matthijs L. Becker et al.   NEUROGENETICS

Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions

(2010) G Ahlin et al.   PHARMACOGENOMICS JOURNAL

Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron

(2010) M V Tzvetkov et al.   PHARMACOGENOMICS JOURNAL

Organic cation transporter pharmacogenomics and drug–drug interaction

(2010) Anne T Nies et al.   Expert Review of Clinical Pharmacology

Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters

(2009) S. Hu et al.   CLINICAL CANCER RESEARCH

Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia

(2009) D. H. Kim et al.   CLINICAL CANCER RESEARCH

The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin

(2009) M V Tzvetkov et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study

(2009) K. Zhou et al.   DIABETES

Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver

(2009) Anne T. Nies et al.   HEPATOLOGY

Transport of Lamivudine [(-)- -L-2',3'-Dideoxy-3'-thiacytidine] and High-Affinity Interaction of Nucleoside Reverse Transcriptase Inhibitors with Human Organic Cation Transporters 1, 2, and 3

(2009) G. Minuesa et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Five Amino Acids in the Innermost Cavity of the Substrate Binding Cleft of Organic Cation Transporter 1 Interact with Extracellular and Intracellular Corticosterone

(2009) C. Volk et al.   MOLECULAR PHARMACOLOGY

Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus

(2009) M L Becker et al.   PHARMACOGENOMICS JOURNAL

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

(2008) A. Giannoudis et al.   BLOOD

Genetics of inflammatory bowel disease: clues to pathogenesis

(2008) H. Zhang et al.   BRITISH MEDICAL BULLETIN

Drug Transporter and Cytochrome P450 mRNA Expression in Human Ocular Barriers: Implications for Ocular Drug Disposition

(2008) T. Zhang et al.   DRUG METABOLISM AND DISPOSITION

Interactions of Organic Anion Transporters and Organic Cation Transporters With Mycotoxins

(2008) Kittipong Tachampa et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients

(2008) Otto Zach et al.   LEUKEMIA & LYMPHOMA

cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects

(2008) Katherine S. Lovejoy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA